Document Detail


Comparison of the effects of atorvastatin and simvastatin in women with polycystic ovary syndrome: A prospective, randomized study.
MedLine Citation:
PMID:  20146169     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Polycystic ovary syndrome (PCOS) is associated with hyperandrogenism, insulin resistance (IR), and chronic inflammation. Simvastatin improves endocrine/clinical aspects of PCOS and decreases systemic inflammation in PCOS. There have been no comparative studies carried out regarding the effects of different statin treatment in PCOS. We aimed to assess the effects of two different statin treatments on various metabolic, endocrine, oxidative and inflammatory factors in PCOS. DESIGN: Prospective, randomized clinical trial METHODS: Sixty-four (64) women with PCOS were included in the study. Group 1 had (atorvastatin, 20lmg daily; n=32) or group 2 had (simvastatin, 20l mg daily n=32). The metabolic, endocrine, inflammatory and oxidative profiles were evaluated. RESULTS: Group 1 resulted in a significant reduction in the HOMA index and fasting insulin (-26.9+/-9.6%, -26.2+/-10.8%, P<0.01, respectively).CRP levels decreased by 63.6+/-15.9% in group 1 (P<0.01), whereas in the group 2 it decreased by 34.6+/-10.7% (P<0.05). Serum levels of LH declined by 19.1+/-4.5% (P<0.05) in the group 1 and by 39.3+/-11.9% (P<0.01) in the group 2. FAI decreased by -20+/-9.9% in group 1 (P<0.05) and it decreased by -38.7+/-13.8% in the group 2 (P<0.01). MDA levels decreased by 32.6+/-9.6% in group 1 (P<0.05), whereas in the group 2 it decreased by 30.3+/-10.9% (P<0.01). HOMA index and fasting insulin showed a reduction but not reached statistically significance in the group 2 (8.3+/-1.9%, 3.0+/-0.8%, P>0.05, respectively). CONCLUSION: Both the statins are effective in reducing inflammation, hyperandrogenemia, oxidative stress and metabolic parameters. While atorvastatin has more noticeable effects on fasting insulin and insulin sensitivity, simvastatin has a dominant effect on total T in PCOS women.
Authors:
C Kaya; R Pabuccu; S D Cengiz; I D?nder
Related Documents :
11932299 - Relationship of calpain-10 genotype to phenotypic features of polycystic ovary syndrome.
10626549 - Endocrinology and metabolism after premature pubarche in girls.
14570659 - Novel, adjustable, clinical bymixer measures mixed expired gas concentrations in anesth...
19298279 - Is there a role for insulin resistance in nonobese patients with idiopathic hirsutism?
8473449 - Sandostatin has no direct effect on ovarian steroidogenesis in vitro.
18850379 - Body fat composition and distribution in women with polycystic ovary syndrome.
14602749 - Effects of growth hormone (gh) on ghrelin, leptin, and adiponectin in gh-deficient pati...
11467319 - Noninvasive glucose monitoring with optical heterodyne technique.
22162189 - A synthetic approach toward a self-regulated insulin delivery system.
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial     Date:  2010-02-09
Journal Detail:
Title:  Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association     Volume:  118     ISSN:  1439-3646     ISO Abbreviation:  Exp. Clin. Endocrinol. Diabetes     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-03-15     Completed Date:  2010-06-24     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9505926     Medline TA:  Exp Clin Endocrinol Diabetes     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  161-6     Citation Subset:  IM    
Copyright Information:
J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart * New York.
Affiliation:
Ufuk University, Department of Obstetrics and Gynecology. kayacemil000@yahoo.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
C-Reactive Protein / drug effects
Fasting
Female
Heptanoic Acids / therapeutic use*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Hyperandrogenism / drug therapy
Inflammation / drug therapy
Insulin / blood
Insulin Resistance / physiology
Luteinizing Hormone / blood,  drug effects
Oxidative Stress / drug effects
Polycystic Ovary Syndrome / drug therapy*
Prospective Studies
Pyrroles / therapeutic use*
Simvastatin / therapeutic use*
Testosterone / blood
Young Adult
Chemical
Reg. No./Substance:
0/Heptanoic Acids; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Pyrroles; 11061-68-0/Insulin; 110862-48-1/atorvastatin; 58-22-0/Testosterone; 79902-63-9/Simvastatin; 9002-67-9/Luteinizing Hormone; 9007-41-4/C-Reactive Protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of growth hormone (GH) on fasting and postprandial metabolism in GH deficiency.
Next Document:  Association of LPR5 polymorphism with bone mass density and cholesterol level in population of Chine...